O
IPSC icon

OrbiMed’s Century Therapeutics IPSC Stock Holding History

OrbiMed’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-307,047
Closed -$4.87M – 155
2021
Q4 		$4.87M Sell
307,047
-100,000
-25% -$1.88M 0.06% 136
2021
Q3 		$10.2M Hold
407,047
– – 0.11% 125
2021
Q2 		$11.9M Buy
+407,047
New +$10.3M 0.12% 120

Other funds holding IPSC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

OrbiMed's IPSC Position: Q1 2022 in Review

OrbiMed sold out of Century Therapeutics (IPSC) in Q1 2022, closing a stake of 307,047 shares — an estimated $4.87M sold.

OrbiMed first reported a position in IPSC in Q2 2021 and held it in 3 quarters. The position peaked at $11.9M in Q2 2021. 52 funds tracked by Wall St. Rank hold IPSC as of Q1 2022.

  • OrbiMed reported no remaining Century Therapeutics position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 307,047 Century Therapeutics shares in Q1 2022, an estimated $4.87M.
  • OrbiMed first reported a position in Century Therapeutics in Q2 2021 and held it in 3 quarters.
  • OrbiMed's Century Therapeutics position peaked at $11.9M in Q2 2021.
  • 52 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.